CYP2C19 Substrates

    CYP2C19 substrates include, but are not limited to, amitriptyline, citalopram, clobazam, clopidogrel, clomipramine, imipramine, most proton pump inhibitors (e.g., omeprazole, pantoprazole, rabeprazole), and voriconazole. See glossary page for more information.

    Summary

    CYP2C19 substrates are compounds that are metabolized by CYP2C19 (a cytochrome P450 enzyme), but do not necessarily affect its activity.

    In the presence of CYP2C19 inhibitors or inducers, the metabolism of CYP2C19 substrates can be affected.

    The table below outlines some of the most common or clinically relevant CYP2C19 substrates.[1][2][3] Importantly, this list is not exhaustive.

    CYP2C19 Substrates
    Amitriptyline
    Citalopram
    Clobazam
    Clomipramine
    Clopidogrel*
    Diazepam
    Imipramine
    Lansoprazole
    Omeprazole
    Pantoprazole
    Phenytoin
    Rabeprazole
    Ranitidine
    Voriconazole

    * Prodrugs are indicated with an asterisk

    References

    1. ^Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu YDrug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.Clin Pharmacokinet.(2021-May)
    2. ^Zanger UM, Schwab MCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.Pharmacol Ther.(2013-Apr)
    3. ^Hakkola J, Hukkanen J, Turpeinen M, Pelkonen OInhibition and induction of CYP enzymes in humans: an update.Arch Toxicol.(2020-Nov)